Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 20/3012% below fair value
$167.40−2.00 (-1.18%)
Close on Nov 13, 2026Market cap $17.02BP/E 24.8Yield –
Neurocrine Biosciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Neurocrine Biosciences's enterprise value was $17.33B on Nov 11, 2026, against $14.06B a year earlier. Over the last 5 years it ranged from $6.73B to $17.33B, with a median of $11.50B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $17.33B | +33.0% |
| 2025 | Dec 31, 2025 | $13.03B | +3.5% |
| 2024 | Dec 31, 2024 | $12.59B | +6.3% |
| 2023 | Dec 29, 2023 | $11.84B | +10.9% |
| 2022 | Dec 30, 2022 | $10.68B | +46.1% |
| 2021 | Dec 31, 2021 | $7.31B | -8.7% |
| 2020 | Dec 31, 2020 | $8.01B | -13.2% |
| 2019 | Dec 31, 2019 | $9.22B | +47.0% |
| 2018 | Dec 31, 2018 | $6.27B | -4.8% |
| 2017 | Dec 29, 2017 | $6.59B | +102.1% |
| 2016 | Dec 30, 2016 | $3.26B | -31.9% |
| 2015 | Dec 31, 2015 | $4.79B | +215.7% |
| 2014 | Dec 31, 2014 | $1.52B | +221.6% |
| 2013 | Dec 31, 2013 | $472.07M | +46.3% |
| 2012 | Dec 31, 2012 | $322.57M | -9.9% |
| 2011 | Dec 30, 2011 | $358.03M | +36.8% |
| 2010 | Dec 31, 2010 | $261.68M | – |
See a number that looks wrong?